NuCana (NASDAQ:NCNA) just reported results for the second quarter of 2024. NuCana reported earnings per share of -15 cents. This was above the analyst estimate for EPS of -$2.35. The company did ...

New research on a chemical substance from caterpillar fungus, known for its potential as a cancer treatment.

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Nucana (NCNA – Research Report), with a price target of $20.00. The company’s shares ...

NuCana Plc is a clinical stage biopharmaceutical company. It engages in the business of developing a portfolio of new medicines to treat patients with cancer. The company was founded by Hugh ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

EDINBURGH, United Kingdom, Sept. 25, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...